Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience

UĞURLU S., Ergezen B., Egeli B. H., Selvi O., Ozdogan H.

RHEUMATOLOGY, cilt.60, sa.5, ss.2327-2332, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1093/rheumatology/keaa596
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.2327-2332
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives. Anakinra is proven to be effective in controlled trials in terms of attack frequency and subclinical inflammation in colchicine-resistant patients. The objective of this study was to review the patients followed in our single centre with FMF who received anakinra because of insufficient colchicine response.